PO.TB03.06 · 肿瘤生物学
肿瘤外泌体启动的中性粒细胞IRG1/衣康酸轴唤醒休眠肿瘤细胞并促进肺转移
Tumor exosome-initiated neutrophil IRG1/itaconate axis awakens dormant tumor cells and promotes lung metastasis
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
目的:肿瘤细胞休眠和代谢重编程是转移复发中的关键事件。然而,其机制——尤其是肺转移前生态位及其相关代谢改变如何唤醒休眠的播散性肿瘤细胞(DTC)——仍不清楚。本研究旨在解析从原发肿瘤来源外泌体到转移前肺中DTC再激活的级联过程,具体鉴定驱动这一过程的关键代谢物介导通路。
材料/方法:我们采用了多种自发性肺转移小鼠模型(如B16-F10、Lewis)。为全面剖析转移前生态位,我们对肺组织进行了非靶向代谢组学以鉴定差异富集的代谢物,并进行单细胞RNA测序(scRNA-seq)以确定Irg1的细胞来源。其他关键技术包括:用于转移追踪的体内成像和H&E染色;生成带Mrp8-Cre的Irg1 flox/flox小鼠以实现中性粒细胞特异性Irg1缺失;分选的肺泡巨噬细胞的RNA-seq;用于验证衣康酸介导的LATS2烷基化的免疫共沉淀和Western印迹;用于YAP1核转位的染色质免疫沉淀(ChIP)。
结果:我们描绘了一条驱动肺内转移再激活的顺序通路。最初,原发肿瘤来源的外泌体教育SPP1+肺泡巨噬细胞增强CXCL2的产生并随之招募中性粒细胞。随后,这些浸润肺部的中性粒细胞特异性表达Irg1,导致代谢物衣康酸在转移前生态位内显著积累。机制上,衣康酸在Hippo通路关键上游激酶LATS2的C910和C911位点直接烷基化休眠的DTC。这一修饰抑制了LATS2磷酸化YAP1的能力,从而促进未磷酸化YAP1的核转位以激活促增殖转录程序,迫使DTC退出休眠。关键的是,通过中性粒细胞特异性Irg1基因消融或CXCR2药理学抑制均可破坏整个轴,两者都显著减少了肿瘤肺转移。
结论:我们的工作揭示了一种新范式,即肿瘤外泌体-中性粒细胞轴通过代谢物介导的蛋白烷基化驱动转移再激活。我们确定中性粒细胞-IRG1-衣康酸轴是这一过程中的关键信号级联,我们的发现表明,无论是在上游靶向CXCR2还是在代谢物衣康酸层面对该轴进行治疗性靶向,都代表了预防肿瘤肺转移的可行策略。
查看英文原文 English abstract
Purpose/Objective(s): Tumor cell dormancy and metabolic reprogramming are critical events in metastatic relapse. However, the mechanisms, particularly how the lung pre-metastatic niche and its associated metabolic alterations awaken dormant disseminated tumor cells (DTCs), remain elusive. This study aims to decipher the cascade from primary tumor-derived exosomes to DTC reactivation in the pre-metastatic lung, specifically identifying the key metabolite-mediated pathway driving this process.
Materials/Methods: We employed multiple mouse models of spontaneous lung metastasis (e.g., B16-F10, Lewis). To comprehensively profile the pre-metastatic niche, we performed untargeted metabolomics on lung tissues to identify differentially enriched metabolites, and single-cell RNA sequencing (scRNA-seq) to delineate the cellular source of Irg1 . Other key techniques included: in vivo imaging and H&E staining for metastasis tracking; generation of Irg1 flox/flox mice with Mrp8-Cre for neutrophil-specific Irg1 deletion; RNA-seq of sorted alveolar macrophages; co-immunoprecipitation and Western blotting for itaconate-mediated LATS2 alkylation validation; chromatin immunoprecipitation (ChIP) for YAP1 nuclear translocation.
Results: We delineated a sequential pathway driving metastatic reactivation in the lung. Initially, primary tumor-derived exosomes educated SPP1 + alveolar macrophages to bolster the production of CXCL2 and ensue neutrophil recruitment. Subsequently, these lung-infiltrating neutrophils specifically expressed Irg1 , resulting in a marked accumulation of the metabolite itaconate within the pre-metastatic niche. Mechanistically, itaconate directly alkylated dormant DTCs at the C910 and C911 site of the key upstream kinase LATS2 in the Hippo pathway. This modification inhibited the LATS2's capacity to phosphorylate YAP1, thereby promoting the nuclear translocation of unphosphorylated YAP1 to activate a pro-proliferative transcriptional program, forcing DTCs to exit dormancy. Crucially, this entire axis was disrupted by either neutrophil-specific genetic ablation of Irg1 or pharmacological inhibition of CXCR2, both of which significantly reduced tumor lung metastasis.
Conclusions: Our work unveils a novel paradigm in which the tumor exosome-neutrophil axis drives metastatic reactivation via metabolite-mediated protein alkylation. We pinpoint the neutrophil-IRG1-itaconate axis as a pivotal signaling cascade in this process, and our findings demonstrate that therapeutic targeting of this axis, either upstream at CXCR2 or at the metabolite itaconate, represents a viable strategy to prevent tumor lung metastasis.
利益披露 Disclosure
Y. Deng, None..
J. Lu, None..
X. Yang, None..
L. Kong, None..
C. Wan, None..
K. Yang, None.